Mark Newman

Chief Tech/Sci/R&D Officer at GEOVAX LABS, INC.

Net worth: - $ as of 2024-03-30

69 year

22 connections

Health Technology

Consumer Services

Technology Services

Profile

Mark J.
Newman is the founder of Newmark Diagnostics LLC, which was founded in 2016.
He is currently the Chief Scientific Officer at GeoVax Labs, Inc. since 2020.
Dr. Newman is also a Member at Louisiana State University.
He received his undergraduate and graduate degrees from The Ohio State University and his doctorate from John Curtin School of Medical Research.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
GEOVAX LABS, INC. -.--%	2024-03-10	0 ( -.--% )	- $	2024-03-30

Mark Newman active positions

Companies	Position	Start
GEOVAX LABS, INC.	Chief Tech/Sci/R&D Officer	2020-08-24

All active positions of Mark Newman

Former positions of Mark Newman

Companies	Position	End
GEOVAX LABS, INC.	Chief Tech/Sci/R&D Officer	2012-12-31
IDM Pharma, Inc. IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	2011-04-27
Emergent Travel Health, Inc. Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA.	Chief Tech/Sci/R&D Officer	2009-11-30
Pharmexa A/S Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration	Chief Tech/Sci/R&D Officer	2008-11-30
Epimmune, Inc.	Chief Tech/Sci/R&D Officer	2005-11-30

See the detail of Mark Newman's experience

Training of Mark Newman

The Ohio State University	Graduate Degree
John Curtin School of Medical Research	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Newman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
GEOVAX LABS, INC.	Health Technology

Private companies	5
Epimmune, Inc.	Health Technology
Emergent Travel Health, Inc. Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA.	Technology Services
Pharmexa A/S Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration	Health Technology
IDM Pharma, Inc. IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.	Health Technology
Newmark Diagnostics LLC

See company connections